Esther Krug, MD
Endocrinology, Diabetes & Metabolism · Baltimore, MDNPI 1699713610
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,200 of the $1,541 with a category attached, or 77.9%. Corcept Therapeutics accounts for 77.9% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $1,231 and has fallen 97.5% since, to $30 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in MD, where the typical reported total is $1,404.
Across 20 payments — averaging $77.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$1K
- Amgen$59
- Radius Health, Inc.$46
- Medtronic$37
- AbbVie$32
- Amphastar Pharmaceuticals, Inc.$30
- plus $138 from 8 others
Across 5 payments — averaging $4312.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dexcom, Inc.$22K
What the payments were for
- Speaking & faculty fees$1,20078%
- Food & beverage$32921%
- Education$121%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 1 | $1,200 |
| Amgen | 3 | $59 |
| Radius Health, Inc. | 2 | $46 |
| Medtronic(2 entities) | 2 | $37 |
| AbbVie | 2 | $32 |
| Amphastar Pharmaceuticals, Inc. | 2 | $30 |
| Novo Nordisk | 1 | $25 |
| Valeritas, Inc. | 1 | $23 |
| Novartis | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Insulet Corporation | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
| Boehringer Ingelheim | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$1,200
How this compares
$1,541 in reported general payments places this provider in the 50th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 231 | $308,609 |
| TrulicityDulaglutide | 184 | $252,675 |
| JardianceEmpagliflozin | 279 | $222,123 |
| ProliaDenosumab | 101 | $168,615 |
| Somatuline DepotLanreotide Acetate | 21 | $145,001 |
| MounjaroTirzepatide | 63 | $112,620 |
| Teriparatide | 32 | $82,550 |
| CreonLipase/Protease/Amylase | 22 | $45,810 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 77 | $42,044 |
| JentaduetoLinagliptin/Metformin Hcl | 55 | $34,809 |
| Norditropin FlexproSomatropin | 11 | $32,084 |
| Praluent PenAlirocumab | 37 | $30,532 |
| Repatha SureclickEvolocumab | 32 | $27,600 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $25,737 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 46 | $22,408 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Jentadueto, Synjardy Xr, Tradjenta, Jentadueto Xr | $11 | $312,617431 claims |
| Novo NordiskOzempic | $25 | $308,609231 claims |
| AmgenProlia | $59 | $168,615101 claims |
| AbbVieCreon, Linzess, Synthroid | $32 | $70,52599 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Baltimore
- Philip LevinBaltimore$489K
- Adrian DobsBaltimore$149K
- Todd BrownBaltimore$143K
- Roberto SalvatoriBaltimore$53K
- Nowreen HaqBaltimore$40K
- Asif MohamedBaltimore$31K
- Sherita GoldenBaltimore$27K
- Jean ParkBaltimore$13K
- Mansur ShomaliBaltimore$11K
- Malek CheikhBaltimore$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.